Aarna Biomedical Products Profile
Key Indicators
- Authorised Capital ₹ 0.20 M
as on 31-07-2024
- Paid Up Capital ₹ 0.11 M
as on 31-07-2024
- Company Age 7 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -3.22%
(FY 2023)
- Profit -73.97%
(FY 2023)
- Ebitda -90.46%
(FY 2023)
- Net Worth 1.30%
(FY 2023)
- Total Assets 44.85%
(FY 2023)
About Aarna Biomedical Products
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.20 M and a paid-up capital of Rs 0.11 M, as per Ministry of Corporate Affairs (MCA) records.
Pawan Mehrotra, Kshama Kothari, and Vinod Mehrotra serve as directors at the Company.
- CIN/LLPIN
U33300UP2017PTC091433
- Company No.
091433
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Mar 2017
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Ghaziabad, Uttar Pradesh, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Aarna Biomedical Products Private Limited offer?
Aarna Biomedical Products Private Limited offers a wide range of products and services, including Medical Surgery & Treatment Centres, Medical Treatment Services.
Who are the key members and board of directors at Aarna Biomedical Products?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pawan Mehrotra  | Managing Director | 17-Mar-2017 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Kshama Kothari | Nominee Director | 01-Nov-2019 | Current |
| Vinod Mehrotra | Director | 17-Mar-2017 | Current |
Financial Performance of Aarna Biomedical Products.
Aarna Biomedical Products Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 3.22% decrease. The company also saw a substantial fall in profitability, with a 73.97% decrease in profit. The company's net worth moved up by a moderate rise of 1.3%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aarna Biomedical Products?
In 2023, Aarna Biomedical Products had a promoter holding of 88.68% and a public holding of 11.32%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Aarna Biomedical Products?
Unlock and access historical data on people associated with Aarna Biomedical Products, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aarna Biomedical Products, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aarna Biomedical Products's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
_PRIVATE_LIMITED.webp){kind=small}
